Literature DB >> 26987473

A tumour control probability model for radiotherapy of prostate cancer using magnetic resonance imaging-based apparent diffusion coefficient maps.

Oscar Casares-Magaz1, Uulke A van der Heide2, Jarle Rørvik3, Peter Steenbergen2, Ludvig Paul Muren4.   

Abstract

BACKGROUND AND
PURPOSE: Standard tumour control probability (TCP) models assume uniform tumour cell density across the tumour. The aim of this study was to develop an individualised TCP model by including index-tumour regions extracted form multi-parametric magnetic resonance imaging (MRI) and apparent diffusion coefficient (ADC) maps-based cell density distributions.
MATERIALS AND METHODS: ADC maps in a series of 20 prostate cancer patients were applied to estimate the initial number of cells within each voxel, using three different approaches for the relation between ADC values and cell density: a linear, a binary and a sigmoid relation. All TCP models were based on linear-quadratic cell survival curves assuming α/β=1.93Gy (consistent with a recent meta-analysis) and α set to obtain a 70% of TCP when 77Gy was delivered to the entire prostate in 35 fractions (α=0.18Gy(-1)).
RESULTS: Overall, TCP curves based on ADC maps showed larger differences between individuals than those assuming uniform cell densities. The range of the dose required to reach 50% TCP across the patient cohort was 20.1Gy, 18.7Gy and 13.2Gy using an MRI-based voxel density (linear, binary and sigmoid approach, respectively), compared to 4.1Gy using a constant density.
CONCLUSIONS: Inclusion of tumour-index information together with ADC maps-based cell density increases inter-patient tumour response differentiation for use in prostate cancer RT, resulting in TCP curves with a larger range in D50% across the cohort compared with those based on uniform cell densities.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Apparent diffusion coefficient (ADC); Cell density; Magnetic resonance imaging (MRI); Prostate cancer; Tumour control probability (TCP)

Mesh:

Year:  2016        PMID: 26987473     DOI: 10.1016/j.radonc.2016.02.030

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  9 in total

1.  A radiobiological model of radiotherapy response and its correlation with prognostic imaging variables.

Authors:  Mireia Crispin-Ortuzar; Jeho Jeong; Andrew N Fontanella; Joseph O Deasy
Journal:  Phys Med Biol       Date:  2017-01-31       Impact factor: 3.609

2.  Manual and semi-automated delineation of locally advanced rectal cancer subvolumes with diffusion-weighted MRI.

Authors:  Nathan Hearn; William Bugg; Anthony Chan; Dinesh Vignarajah; Katelyn Cahill; Daisy Atwell; Jim Lagopoulos; Myo Min
Journal:  Br J Radiol       Date:  2020-09-02       Impact factor: 3.039

3.  Uncertainty evaluation of image-based tumour control probability models in radiotherapy of prostate cancer using a visual analytic tool.

Authors:  Oscar Casares-Magaz; Renata G Raidou; Jarle Rørvik; Anna Vilanova; Ludvig P Muren
Journal:  Phys Imaging Radiat Oncol       Date:  2018-01-12

Review 4.  Multimodal imaging for radiation therapy planning in patients with primary prostate cancer.

Authors:  Constantinos Zamboglou; Matthias Eiber; Thomas R Fassbender; Matthias Eder; Simon Kirste; Michael Bock; Oliver Schilling; Kathrin Reichel; Uulke A van der Heide; Anca L Grosu
Journal:  Phys Imaging Radiat Oncol       Date:  2018-11-05

5.  A biological modelling based comparison of radiotherapy plan robustness using photons vs protons for focal prostate boosting.

Authors:  Jesper Pedersen; Oscar Casares-Magaz; Jørgen B B Petersen; Jarle Rørvik; Lise Bentzen; Andreas G Andersen; Ludvig P Muren
Journal:  Phys Imaging Radiat Oncol       Date:  2018-07-18

6.  Determining the optimum tumor control probability model in radiotherapy of glioblastoma multiforme using magnetic resonance imaging data pre- and post- radiation therapy.

Authors:  Shabnam Banisharif; Daryoush Shahbazi-Gahrouei; Ali Akhavan; Naser Rasouli; Saghar Shahbazi-Gahrouei
Journal:  J Res Med Sci       Date:  2022-02-18       Impact factor: 1.852

7.  Focal dose escalation for prostate cancer using 68Ga-HBED-CC PSMA PET/CT and MRI: a planning study based on histology reference.

Authors:  Constantinos Zamboglou; Benedikt Thomann; Khodor Koubar; Peter Bronsert; Tobias Krauss; Hans C Rischke; Ilias Sachpazidis; Vanessa Drendel; Nasr Salman; Kathrin Reichel; Cordula A Jilg; Martin Werner; Philipp T Meyer; Michael Bock; Dimos Baltas; Anca L Grosu
Journal:  Radiat Oncol       Date:  2018-05-02       Impact factor: 3.481

8.  Influence of Urethra Sparing on Tumor Control Probability and Normal Tissue Complication Probability in Focal Dose Escalated Hypofractionated Radiotherapy: A Planning Study Based on Histopathology Reference.

Authors:  Simon K B Spohn; Ilias Sachpazidis; Rolf Wiehle; Benedikt Thomann; August Sigle; Peter Bronsert; Juri Ruf; Matthias Benndorf; Nils H Nicolay; Tanja Sprave; Anca L Grosu; Dimos Baltas; Constantinos Zamboglou
Journal:  Front Oncol       Date:  2021-05-14       Impact factor: 6.244

Review 9.  Medical Imaging Biomarker Discovery and Integration Towards AI-Based Personalized Radiotherapy.

Authors:  Yaru Pang; Hui Wang; He Li
Journal:  Front Oncol       Date:  2022-01-17       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.